BGI’s Real-Time Fluorescent RT-PCR kit for detecting 2019-nCoV(SARS-CoV-2) is a qualitative in vitro nucleic acid amplification assay used to detect SARS-CoV-2 using reverse transcription PCR from throat swab and Bronchoalveolar Lavage Fluid（BALF） samples. The kit is widely used for rapid detection and outbreak control of COVID-19 in China. BGI is distributing its RT-PCR kits to more than 180 countries and regions around the world.
With its high specificity, sensitivity and rapid response, it can effectively assist the diagnosis of disease and improve the diagnosis efficiency.
LOD of 100 copies/mL
No cross-reactivity with human genome and other pathogens including 54 pathogens, such as human coronavirus OC43, 229E, HKU1 and NL63(HCoV-OC43, HCoV-229E, HCoV-HKU1, HCoV-NL63) etc.
Whole-Process Quality Control
An internal control was set to monitor the laboratory procedures including nucleic acid extraction, Revert transcription and amplification in each reaction.
The kits are internationally available, and are currently being distributed to more than 50 countries and regions worldwide. Each kit provides reagents sufficient for 50 reactions.
New 3-in-1 Test For SARS-CoV-2, Influenza A and Influenza B
COVID-19 shares many symptoms with the flu and this fact will, unfortunately, exacerbate the many existing challenges in diagnosing patients with non-specific respiratory symptoms during flu season.
BGI’s new CE certified 3-in-1 test For SARS-CoV-2, Influenza A and Influenza B provide clinicians and doctors with a reliable single-panel test to help quickly and accurately diagnose patients.
The kits are internationally available and can be distributed to several countries and regions worldwide.